---
document_datetime: 2024-10-18 16:28:26
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cyramza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: cyramza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.7119803
conversion_datetime: 2025-12-19 13:37:46.374604
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cyramza

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0054/G            | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS A.7 - Administrative change - Deletion of manufacturing sites | 10/07/2024                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0053   | Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety data on paediatric patients following the outcome of Article 46 procedure EMEA/H/C/002829/P46/009 and based on results from study J1S-MC-JV02 (JV02). This is a randomized, open-label, phase 1/2 study evaluating ramucirumab in paediatric patients and young adults with relapsed, recurrent, or refractory synovial sarcoma. In addition, the MAH took the opportunity to implement editorial updates to the SmPC and the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 21/03/2024   |            | SmPC, Labelling and PL   | SmPC new text No new safety concerns were reported in the limited number of paediatric patients treated with ramucirumab in combination therapy in study J1S-MC-JV02. The efficacy and safety of ramucirumab in combination with gemcitabine and docetaxel compared to gemcitabine and docetaxel alone was evaluated in J1S-MC-JV02 (JV02), a randomised, multicentre, global, Phase 2 study in 23 paediatric patients and young adults aged 36 months to 29 years with relapsed, recurrent, or progressive synovial sarcoma (SS). Randomization (2:1) was stratified by staging at relapse (metastatic disease versus locally advanced). The study was terminated without formal evaluation of the primary PFS endpoint since at the interim futility analysis, JV02 did not meet the pre-specified 60% confidence in treatment superiority (PFS HR of less than 1 for SS). There was one partial response and no complete response in the experimental arm. No responses, complete   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0052   | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/06/2023   | n/a        |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0051   | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/02/2023   | n/a        |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0050   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/12/2022   | 26/01/2024 | SmPC                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| PSUSA/10323 /202204   | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                                                                                                                                                                                                                                       | 01/12/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0049/G             | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                | 29/08/2022   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0043               | Update of section 4.4 and 4.8 of the SmPC in order to add a new warning on heart failure following a detailed cumulative review of post-marketing data. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the package leaflet to include hypothyroidism as a common side effect. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/06/2022   | 25/07/2022 | SmPC, Labelling and PL | SmPC new text In pooled data from ramucirumab clinical trials, cardiac failure was reported at a numerically higher incidence in patients receiving ramucirumab in combination with a variety of chemotherapy regimens, or erlotinib, compared to chemotherapy or erlotinib alone. This increased incidence was not observed in patients receiving ramucirumab compared to placebo from single agent clinical trials. In the post-marketing setting, cardiac failure was observed for ramucirumab, mostly in combination with paclitaxel. Patients should be monitored for clinical signs and symptoms of cardiac failure during treatment, and suspension of treatment should be considered if clinical signs and symptoms of cardiac failure develop. See section 4.8. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                        |            |            |             | Product Characteristics.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------|
| II/0047 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                          | 10/03/2022 | n/a        |             |                            |
| IB/0046 | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                    | 22/02/2022 | n/a        |             |                            |
| II/0044 | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 16/12/2021 | n/a        |             |                            |
| IA/0045 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                    | 18/10/2021 | n/a        |             |                            |
| II/0041 | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol             | 02/09/2021 | n/a        |             |                            |
| IB/0042 | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                         | 21/08/2021 | 18/07/2022 | SmPC and PL |                            |

<div style=\"page-break-after: always\"></div>

| IA/0040   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 18/02/2021   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0039   | Update of section 4.8 of the SmPC in order to add hypothyroidism to the list of adverse reactions with a frequency of common based on the updated reference safety information for ramucirumab. The Package Leaflet is also updated. In addition, minor updates are included to the list of local representatives in the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                      | 04/02/2021   | 18/07/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0038   | Update of sections 4.4 and 4.8 of the SmPC in order to add posterior reversible encephalopathy syndrome (PRES) and dysphonia as a warning and as undesirable effect, respectively. The Labelling and Package Leaflet are updated accordingly. The RMP version 9.3 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 28/05/2020   | 18/07/2022 | SmPC, Labelling and PL | Cases of posterior reversible encephalopathy syndrome (PRES), including fatal cases, have been rarely reported in patients receiving ramucirumab. PRES symptoms may include seizure, headache, nausea/vomiting, blindness, or altered consciousness, with or without associated hypertension. A diagnosis of PRES can be confirmed by brain imaging (e.g., magnetic resonance imaging). Discontinue ramucirumab in patients who experience PRES. The safety of reinitiating ramucirumab in patients who develop PRES and recover is not known. For more information, please refer to the Summary of Product Characteristics. |
| II/0033   | Extension of indication for Cyramza to include in combination with erlotinib, the first-line treatment of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12/12/2019   | 23/01/2020 | SmPC and PL            | Please refer to the Scientific Discussion Cyramza-H-C-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated accordingly. The RMP version 9.1 has also been agreed. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                        | 2829-II-0033                      |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10323 /201904 | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/10/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0037           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30/10/2019 | 23/01/2020 | SmPC and PL            |                                   |
| IA/0036             | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                               | 11/10/2019 | n/a        |                        |                                   |
| R/0031              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/07/2019 | 26/09/2019 | SmPC, Labelling and PL |                                   |
| IB/0035             | B.II.g.5.c - Implementation of changes foreseen in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 05/08/2019 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027   | Extension of indication to include Cyramza as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have an alpha fetoprotein (AFP) of â‰¥ 400 ng/mL, after prior sorafenib therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in accordance. The Package Leaflet is updated in accordance. RMP version 8.3 has been agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 27/06/2019 | 01/08/2019 | SmPC and PL | Please refer to the Scientific Discussion EMEA/H/C/002829/II/0027                                                                                                                                     |
| IB/0034/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                       | 16/07/2019 | n/a        |             |                                                                                                                                                                                                       |
| II/0030   | Update of section 4.8 of the SmPC in order to add haemangioma and thrombotic microangiopathy (TMA) as new adverse drug reactions as common and rare, respectively based on review of clinical trials, post-marketing cases and the published                                                                                                                                                                                                                                                                                   | 04/04/2019 | 01/08/2019 | SmPC and PL | ADRs of haemangioma and thrombotic microangiopathy were reported in ramucirumab clinical trials at a frequency of common (1.5%) and rare (0.03%), respectively, and through post-marketing reporting. |

<div style=\"page-break-after: always\"></div>

|         | The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives for Estonia, Latvia and Lithuania in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                |            |            |          | scientific literature.    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------|
| II/0029 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                | 14/03/2019 | 01/08/2019 | Annex II |                           |
| IB/0028 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                          | 03/01/2019 | n/a        |          |                           |
|         | This was an application for a group of variations. Submission of the final report from study Study I4T- MC-JVCZ (Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma) and Study I4T-MC-JVDB (Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab | 13/12/2018 | 01/08/2019 | Annex II | II/0023/G Dosing Regimens |

<div style=\"page-break-after: always\"></div>

|                     | Gastroesophageal Junction Adenocarcinoma); Annex II of the product information has been updated to remove study I4T-MC-JVDB. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                         |            |            |                 |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10323 /201804 | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 31/10/2018 | n/a        |                 | PRAC Recommendation - maintenance |
| II/0024/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol | 20/09/2018 | 01/08/2019 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | product and any of the test methods is a biol/immunol/immunochemical method                                                                                                                                                                  |            |            |           |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-----------------------------------|
| II/0025             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                        | 13/09/2018 | n/a        |           |                                   |
| II/0022             | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product          | 03/05/2018 | n/a        |           |                                   |
| IG/0898             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 12/02/2018 | 20/09/2018 | Annex II  |                                   |
| PSUSA/10323 /201704 | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                    | 30/11/2017 | n/a        |           | PRAC Recommendation - maintenance |
| IB/0020             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                | 27/09/2017 | 20/09/2018 | Annex II  |                                   |
| N/0018              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 17/05/2017 | 20/09/2018 | Labelling |                                   |
| PSUSA/10323 /201610 | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                    | 05/05/2017 | n/a        |           | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| PSUSA/10323 /201604   | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/12/2016   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IB/0016               | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/10/2016   | n/a   |                                     |
| II/0015/G             | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 15/09/2016   | n/a   |                                     |
| IA/0013/G             | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                               | 01/06/2016   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

| II/0012/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS   | 26/05/2016   | n/a        |                        |                                                                          |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------|
| PSUSA/10323 /201510 | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/05/2016   | n/a        |                        | PRAC Recommendation - maintenance                                        |
| IG/0662             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/02/2016   | 17/02/2017 | SmPC, Labelling and PL |                                                                          |
| II/0004             | Extension of Indication to include a new indication for Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in                                                             | 17/12/2015   | 25/01/2016 | SmPC, Annex II and PL  | Please refer to the published Assessment Report Cyramza H-2829-II-04-AR. |

<div style=\"page-break-after: always\"></div>

|                     | to include an obligation for the MAH to conduct a Post Authorisation Efficacy Study (PAES). In addition, the Marketing authorisation holder (MAH) took the opportunity to correct minor editorial mistakes and to align Annex II to the QRD version 9.1. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                  |            |            |             |                                                                          |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------|
| II/0003             | Extension of Indication to include a new indication for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with progression after platinum-based chemotherapy for CYRAMZA; as a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, one minor typographical error was corrected in section 4.2 of the SmPC. Version 6 of the Risk Management Plan was agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 17/12/2015 | 25/01/2016 | SmPC and PL | Please refer to the published Assessment Report Cyramza H-2829-II-03-AR. |
| PSUSA/10323 /201504 | Periodic Safety Update EU Single assessment - ramucirumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 06/11/2015 | n/a        |             | PRAC Recommendation - maintenance                                        |
| IB/0009/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/10/2015 | n/a        |             |                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Replacement/addition of a site where batch takes place - Change to importer, batch release and quality control testing of the FP - Replacement/addition of a site where batch takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |          | control/testing B.II.b.2.a arrangements control/testing   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------|
| II/0002/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method | 24/09/2015 | 25/01/2016 | Annex II |                                                           |
| IA/0008   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 16/09/2015 | 25/01/2016 | SmPC     |                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0006/G   | This was an application for a group of variations.                                                                                                                                                                                                                       | 13/07/2015   | n/a        |                 |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| IB/0005/G   | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation | 29/05/2015   | n/a        |                 |
| IAIN/0001   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                   | 19/01/2015   | 25/01/2016 | Annex II and PL |